Ann: Application for quotation of securities - PAA, page-48

Hi AD,
Your point regarding failed trials in the past is interesting, I asked Ai Chat and a list of 10 failed clinical trials quickly appeared. Roach. Novartis and Biogen amounts them.

I think those 3 would have a wealth of research regarding the the potential market etc etc, still on their hard drives making their due diligence easier and quicker. I also think they would have a very good idea of what may qualify for ODD status. Remember ODD is not a clinical trial so there is not the same scrutiny on efficacy.

While I think a quick resolution is possible, my idea of quick is mid year not next week. I'm possibly also a bit more cautious on the final price than some on here. But hey if others who are more bullish prove to be correct that's cool.

Cheers

GLTAH